Human secreted proteins and polynucleotides encoding the same

The present application claims the benefit of U.S. Provisional Application Nos. 60/190,638, 60/191,188 and 60/193,639 which were filed on Mar. 20, 2000, Mar. 22, 2000 and Mar. 31, 2000, respectively. These U.S. Provisional Applications are herein incorporated by reference in their entirety.

The present invention relates to the discovery, identification, and characterization of novel human polynucleotides encoding proteins that share sequence similarity with animal secreted proteins such as, inter alia, semiphorins, protein/peptide hormones of the neurohypophysial and oxytocin (neurophysin 1 precursor) family. The invention encompasses the described polynucleotides, host cell expression systems, the encoded proteins, fusion proteins, polypeptides and peptides, antibodies to the encoded proteins and peptides, and genetically engineered animals that either lack or over express the disclosed polynucleotides, antagonists and agonists of the proteins, and other compounds that modulate the expression or activity of the proteins encoded by the disclosed polynucleotides that can be used for diagnosis, drug screening, clinical trial monitoring, and treatment of diseases and disorders.

Secreted proteins are biologically active molecules that have been implicated in a number of biological processes and anomalies such as hyperproliferative disorders, muscle contraction, vasoconstriction and dilation, immunity, development, modulating metabolism, and cancer. In particular, protein hormones have been implicated in, inter alia, autoimmunity, diabetes, osteoporosis, infectious disease, arthritis, and modulating physiological homeostasis, metabolism, and behavior. Examples of biologically active secreted proteins include, but are not limited to, semaphorins which have been implicated in, inter alia, mediating neural processes, cancer, and development. Along with their cognate receptors (i.e., neuropilins), semaphorins act to regulate the organization and fasciculation of nerves in the body.

The present invention relates to the discovery, identification, and characterization of nucleotides that encode novel human proteins, and the corresponding amino acid sequences of these proteins. The novel human proteins (NHPs) described for the first time herein share structural similarity with semaphorin proteins (SEQ ID NOS: 1-5), protein/peptide hormones of the neurohypophysial family (SEQ ID NOS:6-7) and protein/peptide hormones of the oxytocin (neurophysin 1 precursor) family (SEQ ID NOS:8-10).

The novel human nucleic acid sequences described herein, encode alternative proteins/open reading frames (ORFs) of 875, 782, 91 and 89 amino acids in length (see respectively SEQ ID NOS: 2, 4, 7, 9).

The invention also encompasses agonists and antagonists of the described NHPS, including small molecules, large molecules, mutant NHPS, or portions thereof, that compete with native NHP, peptides, and antibodies, as well as nucleotide sequences that can be used to inhibit the expression of the described NHPs (e.g., antisense and ribozyme molecules, and gene or regulatory sequence replacement constructs) or to enhance the expression of the described NHP polynucleotides (e.g., expression constructs that place the described polynucleotide under the control of a strong promoter system), and transgenic animals that express a NHP transgene, or “knock-outs” (which can be conditional) that do not express a functional NHP. Knock-out mice can be produced in several ways, one of which involves the use of mouse embryonic stem cells (“ES cells”) lines that contain gene trap mutations in a murine homolog of at least one of the described NHPS. When the unique NHP sequences described in SEQ ID NOS:1-10 are “knocked-out” they provide a method of identifying phenotypic expression of the particular gene as well as a method of assigning function to previously unknown genes. Additionally, the unique NHP sequences described in SEQ ID NOS:1-10 are useful for the identification of coding sequence and the mapping a unique gene to a particular chromosome.

Further, the present invention also relates to processes for identifying compounds that modulate, i.e., act as agonists or antagonists, of NHP expression and/or NHP activity that utilize purified preparations of the described NHPs and/or NHP product, or cells expressing the same. Such compounds can be used as therapeutic agents for the treatment of any of a wide variety of symptoms associated with biological disorders or imbalances.

The Sequence Listing provides the sequences of the described NHP ORFs that encode the described NHP amino acid sequences. SEQ ID NOS: 5 and 10 describe NHP ORFs and flanking regions.

The NHPs described for the first time herein are novel proteins that may be expressed in, inter alia, human cell lines, human fetal brain, brain, pituitary, cerebellum, spinal cord, thymus, spleen, lymph node, bone marrow, trachea, kidney, fetal liver, prostate, testis, thyroid, adrenal gland, stomach, small intestine, colon, skeletal muscle, uterus, placenta, adipose, esophagus, cervix, rectum, pericardium, fetal kidney, and gene trapped cells.

More particularly, the NHPs that are similar to semaphorins and described for the first time herein in SEQ ID NOS: 1-5, are novel proteins that are expressed in, inter alia, human cell lines, human fetal brain, brain, cerebellum, thymus, spleen, lymph node, kidney, uterus, adipose, esophagus, cervix, rectum, pericardium, placenta, and gene trapped human cells. The NHP described for the first time herein in SEQ ID NOS:6-7 are a novel protein that is expressed in, inter alia, human fetal brain, brain, pituitary, cerebellum, spinal cord, thymus, spleen, lymph node, bone marrow, trachea, kidney, fetal liver, prostate, testis, thyroid, adrenal gland, stomach, small intestine, colon, skeletal muscle, adipose, esophagus, and gene trapped human cell lines. The NHP described for the first time herein in SEQ ID NOS:8-10 is a novel protein that is expressed in, inter alia, human fetal brain, brain, cerebellum, thymus, kidney, fetal liver, prostate, skeletal muscle, esophagus, rectum, pericardium, fetal kidney and gene trapped human cell lines.

The present invention encompasses the nucleotides presented in the Sequence Listing, host cells expressing such nucleotides, the expression products of such nucleotides, and: (a) nucleotides that encode mammalian homologs of the described polynucleotides, including the specifically described NHPs, and the NHP products; (b) nucleotides that encode one or more portions of the NHPs that correspond to functional domains, and the polypeptide products specified by such nucleotide sequences, including but not limited to the novel regions of any active domain(s); (c) isolated nucleotides that encode mutant versions, engineered or naturally occurring, of the described NHPs in which all or a part of at least one domain is deleted or altered, and the polypeptide products specified by such nucleotide sequences, including but not limited to soluble proteins and peptides in which all or a portion of the signal (or hydrophobic transmembrane) sequence is deleted; (d) nucleotides that encode chimeric fusion proteins containing all or a portion of a coding region of an NHP, or one of its domains (e.g., a receptor or ligand binding domain, accessory protein/self-association domain, etc.) fused to another peptide or polypeptide; or (e) therapeutic or diagnostic derivatives of the described polynucleotides such as oligonucleotides, antisense polynucleotides, ribozymes, dsRNA, or gene therapy constructs comprising a sequence first disclosed in the Sequence Listing. As discussed above, the present invention includes: (a) the human DNA sequences presented in the Sequence Listing (and vectors comprising the same) and additionally contemplates any nucleotide sequence encoding a contiguous NHP open reading frame (ORF) that hybridizes to a complement of a DNA sequence presented in the Sequence Listing under highly stringent conditions, e.g., hybridization to filter-bound DNA in 0.5 M NaHPO 4 , 7% sodium dodecyl sulfate (SDS), 1 mM EDTA at 65° C., and washing in 0.1×SSC/0.1% SDS at 68° C. (Ausubel F.M. et al., eds., 1989, Current Protocols in Molecular Biology, Vol. I, Green Publishing Associates, Inc., and John Wiley & sons, Inc., New York, at p. 2.10.3, and encodes a functionally equivalent gene product. Additionally contemplated are any nucleotide sequences that hybridize to the complement of a DNA sequence that encodes and expresses an amino acid sequence presented in the Sequence Listing under moderately stringent conditions, e.g., washing in 0.2×SSC/0.1% SDS at 42° C. (Ausubel et al., 1989, supra), yet still encodes a functionally equivalent NHP product. Functional equivalents of a NHP include naturally occurring NHPs present in other species and mutant NHPs whether naturally occurring or engineered (by site directed mutagenesis, gene shuffling, directed evolution as described in, for example, U.S. Pat. No. 5,837,458). The invention also includes degenerate nucleic acid variants of the disclosed NHP polynucleotide sequences.

Additionally contemplated are polynucleotides encoding NHP ORFs, or their functional equivalents, encoded by polynucleotide sequences that are about 99, 95, 90, or about 85 percent similar or identical to corresponding regions of the nucleotide sequences of the Sequence Listing (as measured by BLAST sequence comparison analysis using, for example, the GCG sequence analysis package using standard default settings).

The invention also includes nucleic acid molecules, preferably DNA molecules, that hybridize to, and are therefore the complements of, the described NHP nucleotide sequences. Such hybridization conditions may be highly stringent or less highly stringent, as described above. In instances where the nucleic acid molecules are deoxyoligonucleotides (“DNA oligos”), such molecules are generally about 16 to about 100 bases long, or about 20 to about 80, or about 34 to about 45 bases long, or any variation or combination of sizes represented therein that incorporate a contiguous region of sequence first disclosed in the Sequence Listing. Such oligonucleotides can be used in conjunction with the polymerase chain reaction (PCR) to screen libraries, isolate clones, and prepare cloning and sequencing templates, etc.

Alternatively, such NHP oligonucleotides can be used as hybridization probes for screening libraries, and assessing gene expression patterns (particularly using a micro array or high-throughput “chip” format). Additionally, a series of the described NHP oligonucleotide sequences, or the complements thereof, can be used to represent all or a portion of the described NHP sequences. An oligonucleotide or polynucleotide sequence first disclosed in at least a portion of one or more of the sequences of SEQ ID NOS: 1-10 can be used as a hybridization probe in conjunction with a solid support matrix/substrate (resins, beads, membranes, plastics, polymers, metal or metallized substrates, crystalline or polycrystalline substrates, etc.). Of particular note are spatially addressable arrays (i.e., gene chips, microtiter plates, etc.) of oligonucleotides and polynucleotides, or corresponding oligopeptides and polypeptides, wherein at least one of the biopolymers present on the spatially addressable array comprises an oligonucleotide or polynucleotide sequence first disclosed in at least one of the sequences of SEQ ID NOS: 1-10, or an amino acid sequence encoded thereby. Methods for attaching biopolymers to, or synthesizing biopolymers on, solid support matrices, and conducting binding studies thereon are disclosed in, inter alia, U.S. Pat. Nos. 5,700,637, 5,556,752, 5,744,305, 4,631,211, 5,445,934, 5,252,743, 4,713,326, 5,424,186, and 4,689,405 the disclosures of which are herein incorporated by reference in their entirety.

Addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-10 can be used to identify and characterize the temporal and tissue specific expression of a gene. These addressable arrays incorporate oligonucleotide sequences of sufficient length to confer the required specificity, yet be within the limitations of the production technology. The length of these probes is within a range of between about 8 to about 2000 nucleotides. Preferably the probes consist of 60 nucleotides and more preferably 25 nucleotides from the sequences first disclosed in SEQ ID NOS:1-10.

For example, a series of the described oligonucleotide sequences, or the complements thereof, can be used in chip format to represent all or a portion of the described sequences. The oligonucleotides, typically between about 16 to about 40 (or any whole number within the stated range) nucleotides in length can partially overlap each other and/or the sequence may be represented using oligonucleotides that do not overlap. Accordingly, the described polynucleotide sequences shall typically comprise at least about two or three distinct oligonucleotide sequences of at least about 8 nucleotides in length that are each first disclosed in the described Sequence Listing. Such oligonucleotide sequences can begin at any nucleotide present within a sequence in the Sequence Listing and proceed in either a sense (5′-to-3′) orientation vis-a-vis the described sequence or in an antisense orientation.

Microarray-based analysis allows the discovery of broad patterns of genetic activity, providing new understanding of gene functions and generating novel and unexpected insight into transcriptional processes and biological mechanisms. The use of addressable arrays comprising sequences first disclosed in SEQ ID NOS:1-10 provides detailed information about transcriptional changes involved in a specific pathway, potentially leading to the identification of novel components or gene functions that manifest themselves as novel phenotypes.

Probes consisting of sequences first disclosed in SEQ ID NOS:1-10 can also be used in the identification, selection and validation of novel molecular targets for drug discovery. The use of these unique sequences permits the direct confirmation of drug targets and recognition of drug dependent changes in gene expression that are modulated through pathways distinct from the drugs intended target. These unique sequences therefore also have utility in defining and monitoring both drug action and toxicity.

As an example of utility, the sequences first disclosed in SEQ ID NOS:1-10 can be utilized in microarrays or other assay formats, to screen collections of genetic material from patients who have a particular medical condition. These investigations can also be carried out using the sequences first disclosed in SEQ ID NOS:1-10 in silico and by comparing previously collected genetic databases and the disclosed sequences using computer software known to those in the art.

Thus the sequences first disclosed in SEQ ID NOS:1-10 can be used to identify mutations associated with a particular disease and also as a diagnostic or prognostic assay.

Although the presently described sequences have been specifically described using nucleotide sequence, it should be appreciated that each of the sequences can uniquely be described using any of a wide variety of additional structural attributes, or combinations thereof. For example, a given sequence can be described by the net composition of the nucleotides present within a given region of the sequence in conjunction with the presence of one or more specific oligonucleotide sequence(s) first disclosed in the SEQ ID NOS: 1-10. Alternatively, a restriction map specifying the relative positions of restriction endonuclease digestion sites, or various palindromic or other specific oligonucleotide sequences can be used to structurally describe a given sequence. Such restriction maps, which are typically generated by widely available computer programs (e.g., the University of Wisconsin GCG sequence analysis package, SEQUENCHER 3.0, Gene Codes Corp., Ann Arbor, Mich., etc.), can optionally be used in conjunction with one or more discrete nucleotide sequence(s) present in the sequence that can be described by the relative position of the sequence relatve to one or more additional sequence(s) or one or more restriction sites present in the disclosed sequence.

For oligonucleotide probes, highly stringent conditions may refer, e.g., to washing in 6×SSC/0.05% sodium pyrophosphate at 37° C. (for 14-base oligos), 48° C. (for 17-base oligos), 55° C. (for 20-base oligos), and 60° C. (for 23-base oligos). These nucleic acid molecules may encode or act as NHP gene antisense molecules, useful, for example, in NHP gene regulation (for and/or as antisense primers in amplification reactions of NHP gene nucleic acid sequences). With respect to NHP gene regulation, such techniques can be used to regulate biological functions. Further, such sequences may be used as part of ribozyme and/or triple helix sequences that are also useful for NHP gene regulation.

Inhibitory antisense or double stranded oligonucleotides can additionally comprise at least one modified base moiety which is selected from the group including but not limited to 5-fluorouracil, 5-bromouracil, 5-chlorouracil, 5-iodouracil, hypoxanthine, xantine, 4-acetylcytosine, 5-(carboxyhydroxylmethyl) uracil, 5-carboxymethylaminomethyl-2-thiouridine, 5-carboxymethylaminomethyluracil, dihydrouracil, beta-D-galactosylqueosine, inosine, N6-isopentenyladenine, 1-methylguanine, 1-methylinosine, 2,2-dimethylguanine, 2-methyladenine, 2-methylguanine, 3-methylcytosine, 5-methylcytosine, N6-adenine, 7-methylguanine, 5-methylaminomethyluracil, 5-methoxyaminomethyl-2-thiouracil, beta-D-mannosylqueosine, 5′-methoxycarboxymethyluracil, 5-methoxyuracil, 2-methylthio-N6-isopentenyladenine, uracil-5-oxyacetic acid (v), wybutoxosine, pseudouracil, queosine, 2-thiocytosine, 5-methyl-2-thiouracil, 2-thiouracil, 4-thiouracil, 5-methyluracil, uracil-5-oxyacetic acid methylester, uracil-5-oxyacetic acid (v), 5-methyl-2-thiouracil, 3-(3-amino-3-N-2-carboxypropyl) uracil, (acp3)w, and 2,6-diaminopurine.

The antisense oligonucleotide can also comprise at least one modified sugar moiety selected from the group including but not limited to arabinose, 2-fluoroarabinose, xylulose, and hexose.

In yet another embodiment, the antisense oligonucleotide will comprise at least one modified phosphate backbone selected from the group consisting of a phosphorothioate, a phosphorodithioate, a phosphoramidothioate, a phosphoramidate, a phosphordiamidate, a methylphosphonate, an alkyl phosphotriester, and a formacetal or analog thereof.

In yet another embodiment, the antisense oligonucleotide is an α-anomeric oligonucleotide. An α-anomeric oligonucleotide forms specific double-stranded hybrids with complementary RNA in which, contrary to the usual β-units, the strands run parallel to each other (Gautier et al. , 1987, Nucl. Acids Res. 15:6625-6641). The oligonucleotide is a 2′-0-methylribonucleotide (Inoue et al., 1987, Nucl. Acids Res. 15:6131-6148), or a chimeric RNA-DNA analogue (Inoue et al ., 1987, FEBS Lett. 215:327-330). Alternatively, double stranded RNA can be used to disrupt the expression and function of a targeted NHP.

Oligonucleotides of the invention can be synthesized by standard methods known in the art, e.g. by use of an automated DNA synthesizer (such as are commercially available from Biosearch, Applied Biosystems, etc.). As examples, phosphorothioate oligonucleotides can be synthesized by the method of Stein et al. (1988, Nucl. Acids Res. 16:3209), and methylphosphonate oligonucleotides can be prepared by use of controlled pore glass polymer supports (Sarin et al., 1988, Proc. Natl. Acad. Sci. U.S.A. 85:7448-7451), etc.

Low stringency conditions are well known to those of skill in the art, and will vary predictably depending on the specific organisms from which the library and the labeled sequences are derived. For guidance regarding such conditions see, for example, Sambrook et al., 1989, Molecular Cloning, A Laboratory Manual (and periodic updates thereof), Cold Springs Harbor Press, N.Y.; and Ausubel et al., 1989, Current Protocols in Molecular Biology, Green Publishing Associates and Wiley Interscience, N.Y.

Alternatively, suitably labeled NHP nucleotide probes can be used to screen a human genomic library using appropriately stringent conditions or by PCR. The identification and characterization of human genomic clones is helpful for identifying polymorphisms (including, but not limited to, nucleotide repeats, microsatellite alleles, single nucleotide polymorphisms, or coding single nucleotide polymorphisms), determining the genomic structure of a given locus/allele, and designing diagnostic tests. For example, sequences derived from regions adjacent to the intron/exon boundaries of the human gene can be used to design primers for use in amplification assays to detect mutations within the exons, introns, splice sites (e.g., splice acceptor and/or donor sites), etc., that can be used in diagnostics and pharmacogenomics.

Further, a NHP gene homolog can be isolated from nucleic acid from an organism of interest by performing PCR using two degenerate or “wobble” oligonucleotide primer pools designed on the basis of amino acid sequences within the NHP products disclosed herein. The template for the reaction may be total RNA, mRNA, and/or cDNA obtained by reverse transcription of mRNA prepared from human or non-human cell lines or tissue known or suspected to express an allele of a NHP gene.

The PCR product can be subcloned and sequenced to ensure that the amplified sequences represent the sequence of the desired NHP gene. The PCR fragment can then be used to isolate a full length cDNA clone by a variety of methods. For example, the amplified fragment can be labeled and used to screen a cDNA library, such as a bacteriophage cDNA library. Alternatively, the labeled fragment can be used to isolate genomic clones via the screening of a genomic library.

PCR technology can also be used to isolate full length cDNA sequences. For example, RNA can be isolated, following standard procedures, from an appropriate cellular or tissue source (i.e., one known, or suspected, to express a NHP gene). A reverse transcription (RT) reaction can be performed on the RNA using an oligonucleotide primer specific for the most 5′ end of the amplified fragment for the priming of first strand synthesis. The resulting RNA/DNA hybrid may then be “tailed” using a standard terminal transferase reaction, the hybrid may be digested with RNase H, and second strand synthesis may then be primed with a complementary primer. Thus, cDNA sequences upstream of the amplified fragment can be isolated. For a review of cloning strategies that can be used, see e.g., Sambrook et al., 1989, supra.

A cDNA encoding a mutant NHP gene can be isolated, for example, by using PCR. In this case, the first cDNA strand may be synthesized by hybridizing an oligo-dT oligonucleotide to mRNA isolated from tissue known or suspected to be expressed in an individual putatively carrying a mutant NHP allele, and by extending the new strand with reverse transcriptase. The second strand of the cDNA is then synthesized using an oligonucleotide that hybridizes specifically to the 5′ end of the normal gene. Using these two primers, the product is then amplified via PCR, optionally cloned into a suitable vector, and subjected to DNA sequence analysis through methods well known to those of skill in the art. By comparing the DNA sequence of the mutant NHP allele to that of a corresponding normal NHP allele, the mutation(s) responsible for the loss or alteration of function of the mutant NHP gene product can be ascertained.

Alternatively, a genomic library can be constructed using DNA obtained from an individual suspected of or known to carry a mutant NHP allele (e.g., a person manifesting a NHP-associated phenotype such as, for example, obesity, high blood pressure, connective tissue disorders, infertility, etc.), or a cDNA library can be constructed using RNA from a tissue known, or suspected, to express a mutant NHP allele. A normal NHP gene, or any suitable fragment thereof, can then be labeled and used as a probe to identify the corresponding mutant NHP allele in such libraries. Clones containing mutant NHP gene sequences can then be purified and subjected to sequence analysis according to methods well known to those skilled in the art.

Additionally, an expression library can be constructed utilizing cDNA synthesized from, for example, RNA isolated from a tissue known, or suspected, to express a mutant NHP allele in an individual suspected of or known to carry such a mutant allele. In this manner, gene products made by the putatively mutant tissue can be expressed and screened using standard antibody screening techniques in conjunction with antibodies raised against a normal NHP product, as described below. (For screening techniques, see, for example, Harlow, E. and Lane, eds., 1988, “Antibodies: A Laboratory Manual”, Cold Spring Harbor Press, Cold Spring Harbor, N.Y.).

Additionally, screening can be accomplished by screening with labeled NHP fusion proteins, such as, for example, alkaline phosphatase-NHP or NHP-alkaline phosphatase fusion proteins. In cases where a NHP mutation results in an expressed gene product with altered function (e.g. , as a result of a missense or a frameshift mutation), polyclonal antibodies to a NHP are likely to cross-react with a corresponding mutant NHP gene product. Library clones detected via their reaction with such labeled antibodies can be purified and subjected to sequence analysis according to methods well known in the art.

The invention also encompasses (a) DNA vectors that contain any of the foregoing NHP coding sequences and/or their complements (i.e., antisense); (b) DNA expression vectors that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences (for example, baculo virus as described in U.S. Pat. No. 5,869,336 herein incorporated by reference); (c) genetically engineered host cells that contain any of the foregoing NHP coding sequences operatively associated with a regulatory element that directs the expression of the coding sequences in the host cell; and (d) genetically engineered host cells that express an endogenous NHP gene under the control of an exogenously introduced regulatory element (i.e., gene activation). As used herein, regulatory elements include, but are not limited to, inducible and non-inducible promoters, enhancers, operators and other elements known to those skilled in the art that drive and regulate expression. Such regulatory elements include but are not limited to the cytomegalovirus (hCMV) immediate early gene, regulatable, viral elements (particularly retroviral LTR promoters), the early or late promoters of SV40 adenovirus, the lac system, the trp system, the TAC system, the TRC system, the major operator and promoter regions of phage lambda, the control regions of fd coat protein, the promoter for 3-phosphoglycerate kinase (PGK), the promoters of acid phosphatase, and the promoters of the yeast α-mating factors.

The present invention also encompasses antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists and agonists of the NHP, as well as compounds or nucleotide constructs that inhibit expression of a NHP gene (transcription factor inhibitors, antisense and ribozyme molecules, or gene or regulatory sequence replacement constructs), or promote the expression of a NHP (e.g., expression constructs in which NHP coding sequences are operatively associated with expression control elements such as promoters, promoter/enhancers, etc.).

The NHPs or NHP peptides, NHP fusion proteins, NHP nucleotide sequences, antibodies, antagonists and agonists can be useful for the detection of mutant NHPs or inappropriately expressed NHPs for the diagnosis of disease. The NHP proteins or peptides, NHP fusion proteins, NHP nucleotide sequences, host cell expression systems, antibodies, antagonists, agonists and genetically engineered cells and animals can be used for screening for drugs (or high throughput screening of combinatorial libraries) effective in the treatment of the symptomatic or phenotypic manifestations of perturbing the normal function of NHP in the body. The use of engineered host cells and/or animals may offer an advantage in that such systems allow not only for the identification of compounds that bind to the endogenous receptor for an NHP, but can also identify compounds that trigger NHP-mediated activities or pathways.

Finally, the NHP products can be used as therapeutics. For example, soluble derivatives such as NHP peptides/domains corresponding to NHPs, NHP fusion protein products (especially NHP-Ig fusion proteins, i.e., fusions of a NHP, or a domain of a NHP, to an IgFc), NHP antibodies and anti-idiotypic antibodies (including Fab fragments), antagonists or agonists (including compounds that modulate or act on downstream targets in a NHP-mediated pathway) can be used to directly treat diseases or disorders. For instance, the administration of an effective amount of soluble NHP, or a NHP-IgFc fusion protein or an anti-idiotypic antibody (or its Fab) that mimics the NHP could activate or effectively antagonize the endogenous NHP receptor. Nucleotide constructs encoding such NHP products can be used to genetically engineer host cells to express such products in vivo; these genetically engineered cells function as “bioreactors” in the body delivering a continuous supply of a NHP, a NHP peptide, or a NHP fusion protein to the body. Nucleotide constructs encoding functional NHPs, mutant NHPs, as well as antisense and ribozyme molecules can also be used in “gene therapy” approaches for the modulation of NHP expression. Thus, the invention also encompasses pharmaceutical formulations and methods for treating biological disorders.

Various aspects of the invention are described in greater detail in the subsections below.

The Nhp Sequences

The cDNA sequences and the corresponding deduced amino acid sequences of the described NHPs are presented in the Sequence Listing. The NHP nucleotides described in SEQ ID NOS:1-5 were obtained from clustered human gene trapped sequences, ESTs, and cDNA isolated from a human placenta cDNA cell library (Edge Biosystems, Gaithersburg, Md.).

The sequences described in SEQ ID NOS:1-5 share limited structural similarity with a variety of proteins, including, but not limited to, semaphorins and collapsing. A polymorphism was identified that results in a translationally silent A-to-G transition at, for example, the position corresponding to nucleotide 2106 of SEQ ID NO:1. Because of their role in neural development, semaphorins have been subject to considerable scientific scrutiny. For example, U.S. Patents Nos. 5,981,222 and 5,935,865, both of which are herein incorporated by reference, describe other semaphorins as well as applications, utilities, and uses that also pertain to the described semphorin-like NHPs.

The cDNA sequence (SEQ ID NO: 6) and the corresponding deduced amino acid sequence (SEQ ID NO: 7) presented in the Sequence Listing were obtained by analyzing human gene trapped sequence tags. The “m” at position 124 of SEQ ID NO:6 represents an A-or-C polymorphism that can result in either a S or a R (preferred) at corresponding amino acid position 42 of SEQ ID NO:7, and the “y” displayed at position 233 of SEQ ID NO:6 represents a C-or-T polymorphism that can result in either a T or a M at corresponding amino acid position 158 of SEQ ID NO:7. The sequences described in SEQ ID NOS:6-7 share limited structural similarity with a variety of proteins, including, but not limited to, protein/peptide hormones of the neurohypophysial family.

The cDNA sequence (SEQ ID NO: 8) and the corresponding deduced amino acid sequence (SEQ ID NO: 9) were obtained by analyzing human gene trapped sequence tags and cDNA clones isolated from a human kidney cDNA library (Edge Biosystems, Gaithersburg, Md.). The sequences described in SEQ ID NOS:8-10 share limited structural similarity with a variety of proteins, including, but not limited to, protein/peptide hormones of the oxytocin (neurophysin 1 precursor) family.

Nhps and Nhp Polypeptides

NHPs, polypeptides, peptide fragments, mutated, truncated, or deleted forms of the NHPs, and/or NHP fusion proteins can be prepared for a variety of uses. These uses include but are not limited to the generation of antibodies, as reagents in diagnostic assays, the identification of other cellular gene products related to a NHP, as reagents in assays for screening for compounds that can be as pharmaceutical reagents useful in the therapeutic treatment of mental, biological, or medical disorders and diseases. Given the similarity information and expression data, the described NHPs can be targeted (by drugs, oligos, antibodies, etc,) in order to treat disease, or to therapeutically augment the efficacy of, for example, chemotherapeutic agents used in the treatment of breast or prostate cancer.

The Sequence Listing discloses the amino acid sequences encoded by the described NHP polynucleotides. The NHPs typically display have initiator methionines in DNA sequence contexts consistent with a translation initiation site.

The NHP amino acid sequences of the invention include the amino acid sequence presented in the Sequence Listing as well as analogues and derivatives thereof. Further, corresponding NHP homologues from other species are encompassed by the invention. In fact, any NHP protein encoded by the NHP nucleotide sequences described above are within the scope of the invention, as are any novel polynucleotide sequences encoding all or any novel portion of an amino acid sequence presented in the Sequence Listing. The degenerate nature of the genetic code is well known, and, accordingly, each amino acid presented in the Sequence Listing, is generically representative of the well known nucleic acid “triplet” codon, or in many cases codons, that can encode the amino acid. As such, as contemplated herein, the amino acid sequences presented in the Sequence Listing, when taken together with the genetic code (see, for example, Table 4-1 at page 109 of “Molecular Cell Biology”, 1986, J. Darnell et al. eds., Scientific American Books, New York, N.Y., herein incorporated by reference) are generically representative of all the various permutations and combinations of nucleic acid sequences that can encode such amino acid sequences.

The invention also encompasses proteins that are functionally equivalent to the NHPs encoded by the presently described nucleotide sequences as judged by any of a number of criteria, including, but not limited to, the ability to bind and cleave a substrate of a NHP, or the ability to effect an identical or complementary downstream pathway, or a change in cellular metabolism (e.g., proteolytic activity, ion flux, tyrosine phosphorylation, etc.). Such functionally equivalent NHP proteins include, but are not limited to, additions or substitutions of amino acid residues within the amino acid sequence encoded by the NHP nucleotide sequences described above, but which result in a silent change, thus producing a functionally equivalent gene product. Amino acid substitutions may be made on the basis of similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and/or the amphipathic nature of the residues involved. For example, nonpolar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid.

A variety of host-expression vector systems can be used to express the NHP nucleotide sequences of the invention. Where, as in the present instance, the NHP peptide or polypeptide is thought to be membrane protein, the hydrophobic regions of the protein can be excised and the resulting soluble peptide or polypeptide can be recovered from the culture media. Such expression systems also encompass engineered host cells that express a NHP, or functional equivalent, in situ. Purification or enrichment of a NHP from such expression systems can be accomplished using appropriate detergents and lipid micelles and methods well known to those skilled in the art. However, such engineered host cells themselves may be used in situations where it is important not only to retain the structural and functional characteristics of the NHP, but to assess biological activity, e.g., in drug screening assays.

The expression systems that may be used for purposes of the invention include but are not limited to microorganisms such as bacteria (e.g., E. coli, B. subtilis ) transformed with recombinant bacteriophage DNA, plasmid DNA or cosmid DNA expression vectors containing NHP nucleotide sequences; yeast (e.g., Saccharomyces, Pichia) transformed with recombinant yeast expression vectors containing NHP nucleotide sequences; insect cell systems infected with recombinant virus expression vectors (e.g., baculovirus) containing NHP sequences; plant cell systems infected with recombinant virus expression vectors (e.g., cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV) or transformed with recombinant plasmid expression vectors (e.g., Ti plasmid) containing NHP nucleotide sequences; or mammalian cell systems (e.g., COS, CHO, BHK, 293, 3T3) harboring recombinant expression constructs containing promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the adenovirus late promoter; the vaccinia virus 7.5K promoter).

In bacterial systems, a number of expression vectors may be advantageously selected depending upon the use intended for the NHP product being expressed. For example, when a large quantity of such a protein is to be produced for the generation of pharmaceutical compositions of or containing NHP, or for raising antibodies to a NHP, vectors that direct the expression of high levels of fusion protein products that are readily purified may be desirable. Such vectors include, but are not limited, to the E. coli expression vector pUR278 (Ruther et al., 1983, EMBO J. 2:1791), in which a NHP coding sequence may be ligated individually into the vector in frame with the lacZ coding region so that a fusion protein is produced; pIN vectors (Inouye & Inouye, 1985, Nucleic Acids Res. 13:3101-3109; Van Heeke & Schuster, 1989, J. Biol. Chem. 264:5503-5509); and the like. pGEX vectors (Pharmacia or American Type Culture Collection) can also be used to express foreign polypeptides as fusion proteins with glutathione S-transferase (GST). In general, such fusion proteins are soluble and can easily be purified from lysed cells by adsorption to glutathione-agarose beads followed by elution in the presence of free glutathione. The PGEX vectors are designed to include thrombin or factor Xa protease cleavage sites so that the cloned target gene product can be released from the GST moiety.

In an insect system, Autographa californica nuclear polyhidrosis virus (AcNPV) is used as a vector to express foreign genes. The virus grows in Spodoptera frugiperda cells. A NHP coding sequence may be cloned individually into non-essential regions (for example the polyhedrin gene) of the virus and placed under control of an AcNPV promoter (for example the polyhedrin promoter). Successful insertion of NHP coding sequence will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (i.e., virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect Spodoptera frugiperda cells in which the inserted sequence is expressed (e.g., see Smith et al., 1983, J. Virol. 46:584; Smith, U.S. Pat. No. 4,215,051).

In mammalian host cells, a number of viral-based expression systems may be utilized. In cases where an adenovirus is used as an expression vector, the NHP nucleotide sequence of interest may be ligated to an adenovirus transcription/translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric gene may then be inserted in the adenovirus genome by in vitro or in vivo recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing a NHP product in infected hosts (e.g., See Logan & Shenk, 1984, Proc. Natl. Acad. Sci. USA 81:3655-3659). Specific initiation signals may also be required for efficient translation of inserted NHP nucleotide sequences. These signals include the ATG initiation codon and adjacent sequences. In cases where an entire NHP gene or cDNA, including its own initiation codon and adjacent sequences, is inserted into the appropriate expression vector, no additional translational control signals may be needed. However, in cases where only a portion of a NHP coding sequence is inserted, exogenous translational control signals, including, perhaps, the ATG initiation codon, must be provided. Furthermore, the initiation codon must be in phase with the reading frame of the desired coding sequence to ensure translation of the entire insert. These exogenous translational control signals and initiation codons can be of a variety of origins, both natural and synthetic. The efficiency of expression may be enhanced by the inclusion of appropriate transcription enhancer elements, transcription terminators, etc. (See Bitter et al., 1987, Methods in Enzymol. 153:516-544).

In addition, a host cell strain may be chosen that modulates the expression of the inserted sequences, or modifies and processes the gene product in the specific fashion desired. Such modifications (e.g., glycosylation) and processing (e.g., cleavage) of protein products may be important for the function of the protein. Different host cells have characteristic and specific mechanisms for the post-translational processing and modification of proteins and gene products. Appropriate cell lines or host systems can be chosen to ensure the correct modification and processing of the foreign protein expressed. To this end, eukaryotic host cells which possess the cellular machinery for proper processing of the primary transcript, glycosylation, and phosphorylation of the gene product may be used. Such mammalian host cells include, but are not limited to, CHO, VERO, BHK, HeLa, COS, MDCK, 293, 3T3, WI38, and in particular, human cell lines.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. For example, cell lines which stably express the NHP sequences described above can be engineered. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with DNA controlled by appropriate expression control elements (e.g., promoter, enhancer sequences, transcription terminators, polyadenylation sites, etc.), and a selectable marker. Following the introduction of the foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. The selectable marker in the recombinant plasmid confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. This method may advantageously be used to engineer cell lines which express the NHP product. Such engineered cell lines may be particularly useful in screening and evaluation of compounds that affect the endogenous activity of the NHP product.

A number of selection systems may be used, including but not limited to the herpes simplex virus thymidine kinase (Wigler, et al., 1977, Cell 11:223), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, 1962, Proc. Natl. Acad. Sci. USA 48:2026), and adenine phosphoribosyltransferase (Lowy, et al., 1980, Cell 22:817) genes can be employed in tk − , hgprt − or aprt − cells, respectively. Also, antimetabolite resistance can be used as the basis of selection for the following genes: dhfr, which confers resistance to methotrexate (Wigler, et al., 1980, Natl. Acad. Sci. USA 77:3567; O'Hare, et al., 1981, Proc. Natl. Acad. Sci. USA 78:1527); gpt, which confers resistance to mycophenolic acid (Mulligan & Berg, 1981, Proc. Natl. Acad. Sci. USA 78:2072); neo, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, et al., 1981, J. Mol. Biol. 150:1); and hygro, which confers resistance to hygromycin (Santerre, et al., 1984, Gene 30:147).

Alternatively, any fusion protein can be readily purified by utilizing an antibody specific for the fusion protein being expressed. For example, a system described by Janknecht et al. allows for the ready purification of non-denatured fusion proteins expressed in human cell lines (Janknecht, et al., 1991, Proc. Natl. Acad. Sci. USA 88:8972-8976). In this system, the gene of interest is subcloned into a vaccinia recombination plasmid such that the gene's open reading frame is translationally fused to an amino-terminal tag consisting of six histidine residues. Extracts from cells infected with recombinant vaccinia virus are loaded onto Ni 2+ nitriloacetic acid-agarose columns and histidine-tagged proteins are selectively eluted with imidazole-containing buffers.

Also encompassed by the present invention are fusion proteins that direct the NHP to a target organ and/or facilitate transport across the membrane into the cytosol. Conjugation of NHPs to antibody molecules or their Fab fragments could be used to target cells bearing a particular epitope. Attaching the appropriate signal sequence to the NHP would also transport the NHP to the desired location within the cell. Alternatively targeting of NHP or its nucleic acid sequence might be achieved using liposome or lipid complex based delivery systems. Such technologies are described in Liposomes:A Practical Approach, New, RRC ed., Oxford University Press, New York and in U.S. Pat. Nos. 4,594,595, 5,459,127, 5,948,767 and 6,110,490 and their respective disclosures which are herein incorporated by reference in their entirety. Additionally embodied are novel protein constructs engineered in such a way that they facilitate transport of the NHP to the target site or desired organ. This goal may be achieved by coupling of the NHP to a cytokine or other ligand that provides targeting specificity, and/or to a protein transducing domain (see generally U.S. applications Ser. Nos. 60/111,701 and 60/056,713, both of which are herein incorporated by reference, for examples of such transducing sequences) to facilitate passage across cellular membranes if needed and can optionally be engineered to include nuclear localization sequences when desired.

Antibodies to NHP Products

Antibodies that specifically recognize one or more epitopes of a NHP, or epitopes of conserved variants of a NHP, or peptide fragments of a NHP are also encompassed by the invention. Such antibodies include but are not limited to polyclonal antibodies, monoclonal antibodies (mAbs), humanized or chimeric antibodies, single chain antibodies, Fab fragments, F(ab′) 2 fragments, fragments produced by a Fab expression library, anti-idiotypic (anti-Id) antibodies, and epitope-binding fragments of any of the above.

The antibodies of the invention may be used, for example, in the detection of NHP in a biological sample and may, therefore, be utilized as part of a diagnostic or prognostic technique whereby patients may be tested for abnormal amounts of NHP. Such antibodies may also be utilized in conjunction with, for example, compound screening schemes for the evaluation of the effect of test compounds on expression and/or activity of a NHP gene product. Additionally, such antibodies can be used in conjunction gene therapy to, for example, evaluate the normal and/or engineered NHP-expressing cells prior to their introduction into the patient. Such antibodies may additionally be used as a method for the inhibition of abnormal NHP activity. Thus, such antibodies may, therefore, be utilized as part of treatment methods.

For the production of antibodies, various host animals may be immunized by injection with a NHP, an NHP peptide (e.g., one corresponding to a functional domain of an NHP), truncated NHP polypeptides (NHP in which one or more domains have been deleted), functional equivalents of the NHP or mutated variant of the NHP. Such host animals may include but are not limited to pigs, rabbits, mice, goats, and rats, to name but a few. Various adjuvants may be used to increase the immunological response, depending on the host species, including but not limited to Freund's adjuvant (complete and incomplete), mineral salts such as aluminum hydroxide or aluminum phosphate, surface active substances such as lysolecithin, pluronic polyols, polyanions, peptides, oil emulsions, and potentially useful human adjuvants such as BCG (bacille Calmette-Guerin) and Corynebacterium parvum. Alternatively, the immune response could be enhanced by combination and or coupling with molecules such as keyhole limpet hemocyanin, tetanus toxoid, diptheria toxoid, ovalbumin, cholera toxin or fragments thereof. Polyclonal antibodies are heterogeneous populations of antibody molecules derived from the sera of the immunized animals.

Monoclonal antibodies, which are homogeneous populations of antibodies to a particular antigen, can be obtained by any technique which provides for the production of antibody molecules by continuous cell lines in culture. These include, but are not limited to, the hybridoma technique of Kohler and Milstein, (1975, Nature 256:495-497; and U.S. Pat. No. 4,376,110), the human B-cell hybridoma technique (Kosbor et al., 1983, Immunology Today 4:72; Cole et al., 1983, Proc. Natl. Acad. Sci. USA 80:2026-2030), and the EBV-hybridoma technique (Cole et al., 1985, Monoclonal Antibodies And Cancer Therapy, Alan R. Liss, Inc., pp. 77-96). Such antibodies may be of any immunoglobulin class including IgG, IgM, IgE, IgA, IgD and any subclass thereof. The hybridoma producing the mAb of this invention may be cultivated in vitro or in vivo. Production of high titers of mabs in vivo makes this the presently preferred method of production.

In addition, techniques developed for the production of “chimeric antibodies” (Morrison et al., 1984, Proc. Natl. Acad. Sci., 81:6851-6855; Neuberger et al., 1984, Nature, 312:604-608; Takeda et al., 1985, Nature, 314:452-454) by splicing the genes from a mouse antibody molecule of appropriate antigen specificity together with genes from a human antibody molecule of appropriate biological activity can be used. A chimeric antibody is a molecule in which different portions are derived from different animal species, such as those having a variable region derived from a murine mAb and a human immunoglobulin constant region. Such technologies are described in U.S. Pat. Nos. 6,075,181 and 5,877,397 and their respective disclosures which are herein incorporated by reference in their entirety. Also encompassed by the present invention is the use of fully humanized monoclonal antibodies as described in US Pat. No. 6,150,584 and respective disclosures which are herein incorporated by reference in their entirety.

Alternatively, techniques described for the production of single chain antibodies (U.S. Pat. No. 4,946,778; Bird, 1988, Science 242:423-426; Huston et al., 1988, Proc. Natl. Acad. Sci. USA 85:5879-5883; and Ward et al., 1989, Nature 341:544-546) can be adapted to produce single chain antibodies against NHP gene products. Single chain antibodies are formed by linking the heavy and light chain fragments of the Fv region via an amino acid bridge, resulting in a single chain polypeptide.

Antibody fragments which recognize specific epitopes may be generated by known techniques. For example, such fragments include, but are not limited to: the F(ab′) 2 fragments which can be produced by pepsin digestion of the antibody molecule and the Fab fragments which can be generated by reducing the disulfide bridges of the F(ab′) 2 fragments. Alternatively, Fab expression libraries may be constructed (Huse et al. , 1989, Science, 246:1275-1281) to allow rapid and easy identification of monoclonal Fab fragments with the desired specificity.

Antibodies to a NHP can, in turn, be utilized to generate anti-idiotype antibodies that “mimic” a given NHP, using techniques well known to those skilled in the art. (See, e.g., Greenspan & Bona, 1993, FASEB J 7(5):437-444; and Nissinoff, 1991, J. Immunol. 147(8):2429-2438). For example antibodies which bind to a NHP domain and competitively inhibit the binding of NHP to its cognate receptor can be used to generate anti-idiotypes that “mimic” the NHP and, therefore, bind and activate or neutralize a receptor. Such anti-idiotypic antibodies or Fab fragments of such anti-idiotypes can be used in therapeutic regimens involving a NHP mediated pathway.

The present invention is not to be limited in scope by the specific embodiments described herein, which are intended as single illustrations of individual aspects of the invention, and functionally equivalent methods and components are within the scope of the invention. Indeed, various modifications of the invention, in addition to those shown and described herein will become apparent to those skilled in the art form the foregoing description. Such modifications are intended to fall within the scope of the appended claims. All cited publications, patents, and patent applications are here incorporated by reference in their entirety.

<160> NUMBER OF SEQ ID NOS: 10

<210> SEQ ID NO 1

<211> LENGTH: 2628

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 1

atggcctgtg ccctagctgg gaaggtcttc ccaatgggga gctggccagt gt

#ggcacaaa     60

agcctgcact gggccaacaa ggtggaagga gaagcggcag gtggacggca ag

#gccccagc    120

ctccttctct cctccgcccc tcttcccgcc caggactggg tggagccact gc

#cttataag    180

tggtggcctg gtggcagcag agcaaactac aaccggcggc cagcgggacc ag

#agggcggc    240

tctgcaggca ggcggcagcg gtgccctcag ttccccagca tggccccctc gg

#cctgggcc    300

atttgctggc tgctaggggg cctcctgctc catgggggta gctctggccc ca

#gccccggc    360

cccagtgtgc cccgcctgcg gctctcctac cgagacctcc tgtctgccaa cc

#gctctgcc    420

atctttctgg gcccccaggg ctccctgaac ctccaggcca tgtacctaga tg

#agtaccga    480

gaccgcctct ttctgggtgg cctggacgcc ctctactctc tgcggctgga cc

#aggcatgg    540

ccagatcccc gggaggtcct gtggccaccg cagccaggac agagggagga gt

#gtgttcga    600

aagggaagag atcctttgac agagtgcgcc aacttcgtgc gggtgctaca gc

#ctcacaac    660

cggacccacc tgctagcctg tggcactggg gccttccagc ccacctgtgc cc

#tcatcaca    720

gttggccacc gtggggagca tgtgctccac ctggagcctg gcagtgtgga aa

#gtggccgg    780

gggcggtgcc ctcacgagcc cagccgtccc tttgccagca ccttcataga cg

#gggagctg    840

tacacgggtc tcactgctga cttcctgggg cgagaggcca tgatcttccg aa

#gtggaggt    900

cctcggccag ctctgcgttc cgactctgac cagagtctct tgcacgaccc cc

#ggtttgtg    960

atggccgccc ggatccctga gaactctgac caggacaatg acaaggtgta ct

#tcttcttc   1020

tcggagacgg tcccctcgcc cgatggtggc tcgaaccatg tcactgtcag cc

#gcgtgggc   1080

cgcgtctgcg tgaatgatgc tgggggccag cgggtgctgg tgaacaaatg ga

#gcactttc   1140

ctcaaggcca ggctggtctg ctcggtgccc ggccctggtg gtgccgagac cc

#actttgac   1200

cagctagagg atgtgttcct gctgtggccc aaggccggga agagcctcga gg

#tgtacgcg   1260

ctgttcagca ccgtcagtgc cgtgttccag ggcttcgccg tctgtgtgta cc

#acatggca   1320

gacatctggg aggttttcaa cgggcccttt gcccaccgag atgggcctca gc

#accagtgg   1380

gggccctatg ggggcaaggt gcccttccct cgccctggcg tgtgccccag ca

#agatgacc   1440

gcacagccag gacggccttt tggcagcacc aaggactacc cagatgaggt gc

#tgcagttt   1500

gcccgagccc accccctcat gttctggcct gtgcggcctc gacatggccg cc

#ctgtcctt   1560

gtcaagaccc acctggccca gcagctacac cagatcgtgg tggaccgcgt gg

#aggcagag   1620

gatgggacct acgatgtcat tttcctgggg actgactcag ggtctgtgct ca

#aagtcatc   1680

gctctccagg cagggggctc agctgaacct gaggaagtgg ttctggagga gc

#tccaggtg   1740

tttaaggtgc caacacctat caccgaaatg gagatctctg tcaaaaggca aa

#tgctatac   1800

gtgggctctc ggctgggtgt ggcccagctg cggctgcacc aatgtgagac tt

#acggcact   1860

gcctgtgcag agtgctgcct ggcccgggac ccatactgtg cctgggatgg tg

#cctcctgt   1920

acccactacc gccccagcct tggcaagcgc cggttccgcc ggcaggacat cc

#ggcacggc   1980

aaccctgccc tgcagtgcct gggccagagc caggaagaag aggcagtggg ac

#ttgtggca   2040

gccaccatgg tctacggcac ggagcacaat agcaccttcc tggagtgcct gc

#ccaagtct   2100

ccccargctg ctgtgcgctg gctcttgcag aggccagggg atgaggggcc tg

#accaggtg   2160

aagacggacg agcgagtctt gcacacggag cgggggctgc tgttccgcag gc

#ttagccgt   2220

ttcgatgcgg gcacctacac ctgcaccact ctggagcatg gcttctccca ga

#ctgtggtc   2280

cgcctggctc tggtggtgat tgtggcctca cagctggaca acctgttccc tc

#cggagcca   2340

aagccagagg agcccccagc ccggggaggc ctggcttcca ccccacccaa gg

#cctggtac   2400

aaggacatcc tgcagctcat tggcttcgcc aacctgcccc gggtggatga gt

#actgtgag   2460

cgcgtgtggt gcaggggcac cacggaatgc tcaggctgct tccggagccg ga

#gccggggc   2520

aagcaggcca ggggcaagag ctgggcaggg ctggagctag gcaagaagat ga

#agagccgg   2580

gtgcatgccg agcacaatcg gacgccccgg gaggtggagg ccacgtag

#              2628

<210> SEQ ID NO 2

<211> LENGTH: 875

<212> TYPE: PRT

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 2

Met Ala Cys Ala Leu Ala Gly Lys Val Phe Pr

#o Met Gly Ser Trp Pro

1               5

#                10

#                15

Val Trp His Lys Ser Leu His Trp Ala Asn Ly

#s Val Glu Gly Glu Ala

20

#            25

#            30

Ala Gly Gly Arg Gln Gly Pro Ser Leu Leu Le

#u Ser Ser Ala Pro Leu

35

#        40

#        45

Pro Ala Gln Asp Trp Val Glu Pro Leu Pro Ty

#r Lys Trp Trp Pro Gly

50

#    55

#    60

Gly Ser Arg Ala Asn Tyr Asn Arg Arg Pro Al

#a Gly Pro Glu Gly Gly

65

#70

#75

#80

Ser Ala Gly Arg Arg Gln Arg Cys Pro Gln Ph

#e Pro Ser Met Ala Pro

85

#                90

#                95

Ser Ala Trp Ala Ile Cys Trp Leu Leu Gly Gl

#y Leu Leu Leu His Gly

100

#           105

#           110

Gly Ser Ser Gly Pro Ser Pro Gly Pro Ser Va

#l Pro Arg Leu Arg Leu

115

#       120

#       125

Ser Tyr Arg Asp Leu Leu Ser Ala Asn Arg Se

#r Ala Ile Phe Leu Gly

130

#   135

#   140

Pro Gln Gly Ser Leu Asn Leu Gln Ala Met Ty

#r Leu Asp Glu Tyr Arg

145                 1

#50                 1

#55                 1

#60

Asp Arg Leu Phe Leu Gly Gly Leu Asp Ala Le

#u Tyr Ser Leu Arg Leu

165

#               170

#               175

Asp Gln Ala Trp Pro Asp Pro Arg Glu Val Le

#u Trp Pro Pro Gln Pro

180

#           185

#           190

Gly Gln Arg Glu Glu Cys Val Arg Lys Gly Ar

#g Asp Pro Leu Thr Glu

195

#       200

#       205

Cys Ala Asn Phe Val Arg Val Leu Gln Pro Hi

#s Asn Arg Thr His Leu

210

#   215

#   220

Leu Ala Cys Gly Thr Gly Ala Phe Gln Pro Th

#r Cys Ala Leu Ile Thr

225                 2

#30                 2

#35                 2

#40

Val Gly His Arg Gly Glu His Val Leu His Le

#u Glu Pro Gly Ser Val

245

#               250

#               255

Glu Ser Gly Arg Gly Arg Cys Pro His Glu Pr

#o Ser Arg Pro Phe Ala

260

#           265

#           270

Ser Thr Phe Ile Asp Gly Glu Leu Tyr Thr Gl

#y Leu Thr Ala Asp Phe

275

#       280

#       285

Leu Gly Arg Glu Ala Met Ile Phe Arg Ser Gl

#y Gly Pro Arg Pro Ala

290

#   295

#   300

Leu Arg Ser Asp Ser Asp Gln Ser Leu Leu Hi

#s Asp Pro Arg Phe Val

305                 3

#10                 3

#15                 3

#20

Met Ala Ala Arg Ile Pro Glu Asn Ser Asp Gl

#n Asp Asn Asp Lys Val

325

#               330

#               335

Tyr Phe Phe Phe Ser Glu Thr Val Pro Ser Pr

#o Asp Gly Gly Ser Asn

340

#           345

#           350

His Val Thr Val Ser Arg Val Gly Arg Val Cy

#s Val Asn Asp Ala Gly

355

#       360

#       365

Gly Gln Arg Val Leu Val Asn Lys Trp Ser Th

#r Phe Leu Lys Ala Arg

370

#   375

#   380

Leu Val Cys Ser Val Pro Gly Pro Gly Gly Al

#a Glu Thr His Phe Asp

385                 3

#90                 3

#95                 4

#00

Gln Leu Glu Asp Val Phe Leu Leu Trp Pro Ly

#s Ala Gly Lys Ser Leu

405

#               410

#               415

Glu Val Tyr Ala Leu Phe Ser Thr Val Ser Al

#a Val Phe Gln Gly Phe

420

#           425

#           430

Ala Val Cys Val Tyr His Met Ala Asp Ile Tr

#p Glu Val Phe Asn Gly

435

#       440

#       445

Pro Phe Ala His Arg Asp Gly Pro Gln His Gl

#n Trp Gly Pro Tyr Gly

450

#   455

#   460

Gly Lys Val Pro Phe Pro Arg Pro Gly Val Cy

#s Pro Ser Lys Met Thr

465                 4

#70                 4

#75                 4

#80

Ala Gln Pro Gly Arg Pro Phe Gly Ser Thr Ly

#s Asp Tyr Pro Asp Glu

485

#               490

#               495

Val Leu Gln Phe Ala Arg Ala His Pro Leu Me

#t Phe Trp Pro Val Arg

500

#           505

#           510

Pro Arg His Gly Arg Pro Val Leu Val Lys Th

#r His Leu Ala Gln Gln

515

#       520

#       525

Leu His Gln Ile Val Val Asp Arg Val Glu Al

#a Glu Asp Gly Thr Tyr

530

#   535

#   540

Asp Val Ile Phe Leu Gly Thr Asp Ser Gly Se

#r Val Leu Lys Val Ile

545                 5

#50                 5

#55                 5

#60

Ala Leu Gln Ala Gly Gly Ser Ala Glu Pro Gl

#u Glu Val Val Leu Glu

565

#               570

#               575

Glu Leu Gln Val Phe Lys Val Pro Thr Pro Il

#e Thr Glu Met Glu Ile

580

#           585

#           590

Ser Val Lys Arg Gln Met Leu Tyr Val Gly Se

#r Arg Leu Gly Val Ala

595

#       600

#       605

Gln Leu Arg Leu His Gln Cys Glu Thr Tyr Gl

#y Thr Ala Cys Ala Glu

610

#   615

#   620

Cys Cys Leu Ala Arg Asp Pro Tyr Cys Ala Tr

#p Asp Gly Ala Ser Cys

625                 6

#30                 6

#35                 6

#40

Thr His Tyr Arg Pro Ser Leu Gly Lys Arg Ar

#g Phe Arg Arg Gln Asp

645

#               650

#               655

Ile Arg His Gly Asn Pro Ala Leu Gln Cys Le

#u Gly Gln Ser Gln Glu

660

#           665

#           670

Glu Glu Ala Val Gly Leu Val Ala Ala Thr Me

#t Val Tyr Gly Thr Glu

675

#       680

#       685

His Asn Ser Thr Phe Leu Glu Cys Leu Pro Ly

#s Ser Pro Gln Ala Ala

690

#   695

#   700

Val Arg Trp Leu Leu Gln Arg Pro Gly Asp Gl

#u Gly Pro Asp Gln Val

705                 7

#10                 7

#15                 7

#20

Lys Thr Asp Glu Arg Val Leu His Thr Glu Ar

#g Gly Leu Leu Phe Arg

725

#               730

#               735

Arg Leu Ser Arg Phe Asp Ala Gly Thr Tyr Th

#r Cys Thr Thr Leu Glu

740

#           745

#           750

His Gly Phe Ser Gln Thr Val Val Arg Leu Al

#a Leu Val Val Ile Val

755

#       760

#       765

Ala Ser Gln Leu Asp Asn Leu Phe Pro Pro Gl

#u Pro Lys Pro Glu Glu

770

#   775

#   780

Pro Pro Ala Arg Gly Gly Leu Ala Ser Thr Pr

#o Pro Lys Ala Trp Tyr

785                 7

#90                 7

#95                 8

#00

Lys Asp Ile Leu Gln Leu Ile Gly Phe Ala As

#n Leu Pro Arg Val Asp

805

#               810

#               815

Glu Tyr Cys Glu Arg Val Trp Cys Arg Gly Th

#r Thr Glu Cys Ser Gly

820

#           825

#           830

Cys Phe Arg Ser Arg Ser Arg Gly Lys Gln Al

#a Arg Gly Lys Ser Trp

835

#       840

#       845

Ala Gly Leu Glu Leu Gly Lys Lys Met Lys Se

#r Arg Val His Ala Glu

850

#   855

#   860

His Asn Arg Thr Pro Arg Glu Val Glu Ala Th

#r

865                 8

#70                 8

#75

<210> SEQ ID NO 3

<211> LENGTH: 2349

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 3

atggccccct cggcctgggc catttgctgg ctgctagggg gcctcctgct cc

#atgggggt     60

agctctggcc ccagccccgg ccccagtgtg ccccgcctgc ggctctccta cc

#gagacctc    120

ctgtctgcca accgctctgc catctttctg ggcccccagg gctccctgaa cc

#tccaggcc    180

atgtacctag atgagtaccg agaccgcctc tttctgggtg gcctggacgc cc

#tctactct    240

ctgcggctgg accaggcatg gccagatccc cgggaggtcc tgtggccacc gc

#agccagga    300

cagagggagg agtgtgttcg aaagggaaga gatcctttga cagagtgcgc ca

#acttcgtg    360

cgggtgctac agcctcacaa ccggacccac ctgctagcct gtggcactgg gg

#ccttccag    420

cccacctgtg ccctcatcac agttggccac cgtggggagc atgtgctcca cc

#tggagcct    480

ggcagtgtgg aaagtggccg ggggcggtgc cctcacgagc ccagccgtcc ct

#ttgccagc    540

accttcatag acggggagct gtacacgggt ctcactgctg acttcctggg gc

#gagaggcc    600

atgatcttcc gaagtggagg tcctcggcca gctctgcgtt ccgactctga cc

#agagtctc    660

ttgcacgacc cccggtttgt gatggccgcc cggatccctg agaactctga cc

#aggacaat    720

gacaaggtgt acttcttctt ctcggagacg gtcccctcgc ccgatggtgg ct

#cgaaccat    780

gtcactgtca gccgcgtggg ccgcgtctgc gtgaatgatg ctgggggcca gc

#gggtgctg    840

gtgaacaaat ggagcacttt cctcaaggcc aggctggtct gctcggtgcc cg

#gccctggt    900

ggtgccgaga cccactttga ccagctagag gatgtgttcc tgctgtggcc ca

#aggccggg    960

aagagcctcg aggtgtacgc gctgttcagc accgtcagtg ccgtgttcca gg

#gcttcgcc   1020

gtctgtgtgt accacatggc agacatctgg gaggttttca acgggccctt tg

#cccaccga   1080

gatgggcctc agcaccagtg ggggccctat gggggcaagg tgcccttccc tc

#gccctggc   1140

gtgtgcccca gcaagatgac cgcacagcca ggacggcctt ttggcagcac ca

#aggactac   1200

ccagatgagg tgctgcagtt tgcccgagcc caccccctca tgttctggcc tg

#tgcggcct   1260

cgacatggcc gccctgtcct tgtcaagacc cacctggccc agcagctaca cc

#agatcgtg   1320

gtggaccgcg tggaggcaga ggatgggacc tacgatgtca ttttcctggg ga

#ctgactca   1380

gggtctgtgc tcaaagtcat cgctctccag gcagggggct cagctgaacc tg

#aggaagtg   1440

gttctggagg agctccaggt gtttaaggtg ccaacaccta tcaccgaaat gg

#agatctct   1500

gtcaaaaggc aaatgctata cgtgggctct cggctgggtg tggcccagct gc

#ggctgcac   1560

caatgtgaga cttacggcac tgcctgtgca gagtgctgcc tggcccggga cc

#catactgt   1620

gcctgggatg gtgcctcctg tacccactac cgccccagcc ttggcaagcg cc

#ggttccgc   1680

cggcaggaca tccggcacgg caaccctgcc ctgcagtgcc tgggccagag cc

#aggaagaa   1740

gaggcagtgg gacttgtggc agccaccatg gtctacggca cggagcacaa ta

#gcaccttc   1800

ctggagtgcc tgcccaagtc tccccargct gctgtgcgct ggctcttgca ga

#ggccaggg   1860

gatgaggggc ctgaccaggt gaagacggac gagcgagtct tgcacacgga gc

#gggggctg   1920

ctgttccgca ggcttagccg tttcgatgcg ggcacctaca cctgcaccac tc

#tggagcat   1980

ggcttctccc agactgtggt ccgcctggct ctggtggtga ttgtggcctc ac

#agctggac   2040

aacctgttcc ctccggagcc aaagccagag gagcccccag cccggggagg cc

#tggcttcc   2100

accccaccca aggcctggta caaggacatc ctgcagctca ttggcttcgc ca

#acctgccc   2160

cgggtggatg agtactgtga gcgcgtgtgg tgcaggggca ccacggaatg ct

#caggctgc   2220

ttccggagcc ggagccgggg caagcaggcc aggggcaaga gctgggcagg gc

#tggagcta   2280

ggcaagaaga tgaagagccg ggtgcatgcc gagcacaatc ggacgccccg gg

#aggtggag   2340

gccacgtag

#

#

#       2349

<210> SEQ ID NO 4

<211> LENGTH: 782

<212> TYPE: PRT

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 4

Met Ala Pro Ser Ala Trp Ala Ile Cys Trp Le

#u Leu Gly Gly Leu Leu

1               5

#                10

#                15

Leu His Gly Gly Ser Ser Gly Pro Ser Pro Gl

#y Pro Ser Val Pro Arg

20

#            25

#            30

Leu Arg Leu Ser Tyr Arg Asp Leu Leu Ser Al

#a Asn Arg Ser Ala Ile

35

#        40

#        45

Phe Leu Gly Pro Gln Gly Ser Leu Asn Leu Gl

#n Ala Met Tyr Leu Asp

50

#    55

#    60

Glu Tyr Arg Asp Arg Leu Phe Leu Gly Gly Le

#u Asp Ala Leu Tyr Ser

65

#70

#75

#80

Leu Arg Leu Asp Gln Ala Trp Pro Asp Pro Ar

#g Glu Val Leu Trp Pro

85

#                90

#                95

Pro Gln Pro Gly Gln Arg Glu Glu Cys Val Ar

#g Lys Gly Arg Asp Pro

100

#           105

#           110

Leu Thr Glu Cys Ala Asn Phe Val Arg Val Le

#u Gln Pro His Asn Arg

115

#       120

#       125

Thr His Leu Leu Ala Cys Gly Thr Gly Ala Ph

#e Gln Pro Thr Cys Ala

130

#   135

#   140

Leu Ile Thr Val Gly His Arg Gly Glu His Va

#l Leu His Leu Glu Pro

145                 1

#50                 1

#55                 1

#60

Gly Ser Val Glu Ser Gly Arg Gly Arg Cys Pr

#o His Glu Pro Ser Arg

165

#               170

#               175

Pro Phe Ala Ser Thr Phe Ile Asp Gly Glu Le

#u Tyr Thr Gly Leu Thr

180

#           185

#           190

Ala Asp Phe Leu Gly Arg Glu Ala Met Ile Ph

#e Arg Ser Gly Gly Pro

195

#       200

#       205

Arg Pro Ala Leu Arg Ser Asp Ser Asp Gln Se

#r Leu Leu His Asp Pro

210

#   215

#   220

Arg Phe Val Met Ala Ala Arg Ile Pro Glu As

#n Ser Asp Gln Asp Asn

225                 2

#30                 2

#35                 2

#40

Asp Lys Val Tyr Phe Phe Phe Ser Glu Thr Va

#l Pro Ser Pro Asp Gly

245

#               250

#               255

Gly Ser Asn His Val Thr Val Ser Arg Val Gl

#y Arg Val Cys Val Asn

260

#           265

#           270

Asp Ala Gly Gly Gln Arg Val Leu Val Asn Ly

#s Trp Ser Thr Phe Leu

275

#       280

#       285

Lys Ala Arg Leu Val Cys Ser Val Pro Gly Pr

#o Gly Gly Ala Glu Thr

290

#   295

#   300

His Phe Asp Gln Leu Glu Asp Val Phe Leu Le

#u Trp Pro Lys Ala Gly

305                 3

#10                 3

#15                 3

#20

Lys Ser Leu Glu Val Tyr Ala Leu Phe Ser Th

#r Val Ser Ala Val Phe

325

#               330

#               335

Gln Gly Phe Ala Val Cys Val Tyr His Met Al

#a Asp Ile Trp Glu Val

340

#           345

#           350

Phe Asn Gly Pro Phe Ala His Arg Asp Gly Pr

#o Gln His Gln Trp Gly

355

#       360

#       365

Pro Tyr Gly Gly Lys Val Pro Phe Pro Arg Pr

#o Gly Val Cys Pro Ser

370

#   375

#   380

Lys Met Thr Ala Gln Pro Gly Arg Pro Phe Gl

#y Ser Thr Lys Asp Tyr

385                 3

#90                 3

#95                 4

#00

Pro Asp Glu Val Leu Gln Phe Ala Arg Ala Hi

#s Pro Leu Met Phe Trp

405

#               410

#               415

Pro Val Arg Pro Arg His Gly Arg Pro Val Le

#u Val Lys Thr His Leu

420

#           425

#           430

Ala Gln Gln Leu His Gln Ile Val Val Asp Ar

#g Val Glu Ala Glu Asp

435

#       440

#       445

Gly Thr Tyr Asp Val Ile Phe Leu Gly Thr As

#p Ser Gly Ser Val Leu

450

#   455

#   460

Lys Val Ile Ala Leu Gln Ala Gly Gly Ser Al

#a Glu Pro Glu Glu Val

465                 4

#70                 4

#75                 4

#80

Val Leu Glu Glu Leu Gln Val Phe Lys Val Pr

#o Thr Pro Ile Thr Glu

485

#               490

#               495

Met Glu Ile Ser Val Lys Arg Gln Met Leu Ty

#r Val Gly Ser Arg Leu

500

#           505

#           510

Gly Val Ala Gln Leu Arg Leu His Gln Cys Gl

#u Thr Tyr Gly Thr Ala

515

#       520

#       525

Cys Ala Glu Cys Cys Leu Ala Arg Asp Pro Ty

#r Cys Ala Trp Asp Gly

530

#   535

#   540

Ala Ser Cys Thr His Tyr Arg Pro Ser Leu Gl

#y Lys Arg Arg Phe Arg

545                 5

#50                 5

#55                 5

#60

Arg Gln Asp Ile Arg His Gly Asn Pro Ala Le

#u Gln Cys Leu Gly Gln

565

#               570

#               575

Ser Gln Glu Glu Glu Ala Val Gly Leu Val Al

#a Ala Thr Met Val Tyr

580

#           585

#           590

Gly Thr Glu His Asn Ser Thr Phe Leu Glu Cy

#s Leu Pro Lys Ser Pro

595

#       600

#       605

Gln Ala Ala Val Arg Trp Leu Leu Gln Arg Pr

#o Gly Asp Glu Gly Pro

610

#   615

#   620

Asp Gln Val Lys Thr Asp Glu Arg Val Leu Hi

#s Thr Glu Arg Gly Leu

625                 6

#30                 6

#35                 6

#40

Leu Phe Arg Arg Leu Ser Arg Phe Asp Ala Gl

#y Thr Tyr Thr Cys Thr

645

#               650

#               655

Thr Leu Glu His Gly Phe Ser Gln Thr Val Va

#l Arg Leu Ala Leu Val

660

#           665

#           670

Val Ile Val Ala Ser Gln Leu Asp Asn Leu Ph

#e Pro Pro Glu Pro Lys

675

#       680

#       685

Pro Glu Glu Pro Pro Ala Arg Gly Gly Leu Al

#a Ser Thr Pro Pro Lys

690

#   695

#   700

Ala Trp Tyr Lys Asp Ile Leu Gln Leu Ile Gl

#y Phe Ala Asn Leu Pro

705                 7

#10                 7

#15                 7

#20

Arg Val Asp Glu Tyr Cys Glu Arg Val Trp Cy

#s Arg Gly Thr Thr Glu

725

#               730

#               735

Cys Ser Gly Cys Phe Arg Ser Arg Ser Arg Gl

#y Lys Gln Ala Arg Gly

740

#           745

#           750

Lys Ser Trp Ala Gly Leu Glu Leu Gly Lys Ly

#s Met Lys Ser Arg Val

755

#       760

#       765

His Ala Glu His Asn Arg Thr Pro Arg Glu Va

#l Glu Ala Thr

770

#   775

#   780

<210> SEQ ID NO 5

<211> LENGTH: 3568

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 5

acctggggaa gctctggacc ctgagtctct ggaaggactg gaggcctgag gg

#aggcaggg     60

caaggggagg ttccctcggc atggagtccc ctgatgcccc tgtcccctac cc

#caaagcaa    120

gcctggtgag ctgagatggg gcatgtagat gtggggagag gctggggtgc ct

#ggaagcca    180

gatggggaca ggcctgggtg gaagaggctg ggcagtcatc tcttgctggc tc

#tatgaagt    240

gttgccggac ctcaaacacc tgtctaggac atggcgcccc ttgggctggg aa

#tggccctc    300

cacccttacc caggggagct ggagagtctg gccaaagctt cagggggctg ga

#atatcctg    360

gaattggggc agggccagtt tggaaggtct ctgctgtggg cagtggaggg gc

#agagaaca    420

aggcagagcc cagctaggcc cctacccagc ccatcaactt taacctctga tc

#cctgacct    480

cccttccagg ctctctcccc acttgtcact ttgctggagc ctggggacct gc

#atttgtgg    540

acatctctgt acacatggcc tgtgccctag ctgggaaggt cttcccaatg gg

#gagctggc    600

cagtgtggca caaaagcctg cactgggcca acaaggtgga aggagaagcg gc

#aggtggac    660

ggcaaggccc cagcctcctt ctctcctccg cccctcttcc cgcccaggac tg

#ggtggagc    720

cactgcctta taagtggtgg cctggtggca gcagagcaaa ctacaaccgg cg

#gccagcgg    780

gaccagaggg cggctctgca ggcaggcggc agcggtgccc tcagttcccc ag

#catggccc    840

cctcggcctg ggccatttgc tggctgctag ggggcctcct gctccatggg gg

#tagctctg    900

gccccagccc cggccccagt gtgccccgcc tgcggctctc ctaccgagac ct

#cctgtctg    960

ccaaccgctc tgccatcttt ctgggccccc agggctccct gaacctccag gc

#catgtacc   1020

tagatgagta ccgagaccgc ctctttctgg gtggcctgga cgccctctac tc

#tctgcggc   1080

tggaccaggc atggccagat ccccgggagg tcctgtggcc accgcagcca gg

#acagaggg   1140

aggagtgtgt tcgaaaggga agagatcctt tgacagagtg cgccaacttc gt

#gcgggtgc   1200

tacagcctca caaccggacc cacctgctag cctgtggcac tggggccttc ca

#gcccacct   1260

gtgccctcat cacagttggc caccgtgggg agcatgtgct ccacctggag cc

#tggcagtg   1320

tggaaagtgg ccgggggcgg tgccctcacg agcccagccg tccctttgcc ag

#caccttca   1380

tagacgggga gctgtacacg ggtctcactg ctgacttcct ggggcgagag gc

#catgatct   1440

tccgaagtgg aggtcctcgg ccagctctgc gttccgactc tgaccagagt ct

#cttgcacg   1500

acccccggtt tgtgatggcc gcccggatcc ctgagaactc tgaccaggac aa

#tgacaagg   1560

tgtacttctt cttctcggag acggtcccct cgcccgatgg tggctcgaac ca

#tgtcactg   1620

tcagccgcgt gggccgcgtc tgcgtgaatg atgctggggg ccagcgggtg ct

#ggtgaaca   1680

aatggagcac tttcctcaag gccaggctgg tctgctcggt gcccggccct gg

#tggtgccg   1740

agacccactt tgaccagcta gaggatgtgt tcctgctgtg gcccaaggcc gg

#gaagagcc   1800

tcgaggtgta cgcgctgttc agcaccgtca gtgccgtgtt ccagggcttc gc

#cgtctgtg   1860

tgtaccacat ggcagacatc tgggaggttt tcaacgggcc ctttgcccac cg

#agatgggc   1920

ctcagcacca gtgggggccc tatgggggca aggtgccctt ccctcgccct gg

#cgtgtgcc   1980

ccagcaagat gaccgcacag ccaggacggc cttttggcag caccaaggac ta

#cccagatg   2040

aggtgctgca gtttgcccga gcccaccccc tcatgttctg gcctgtgcgg cc

#tcgacatg   2100

gccgccctgt ccttgtcaag acccacctgg cccagcagct acaccagatc gt

#ggtggacc   2160

gcgtggaggc agaggatggg acctacgatg tcattttcct ggggactgac tc

#agggtctg   2220

tgctcaaagt catcgctctc caggcagggg gctcagctga acctgaggaa gt

#ggttctgg   2280

aggagctcca ggtgtttaag gtgccaacac ctatcaccga aatggagatc tc

#tgtcaaaa   2340

ggcaaatgct atacgtgggc tctcggctgg gtgtggccca gctgcggctg ca

#ccaatgtg   2400

agacttacgg cactgcctgt gcagagtgct gcctggcccg ggacccatac tg

#tgcctggg   2460

atggtgcctc ctgtacccac taccgcccca gccttggcaa gcgccggttc cg

#ccggcagg   2520

acatccggca cggcaaccct gccctgcagt gcctgggcca gagccaggaa ga

#agaggcag   2580

tgggacttgt ggcagccacc atggtctacg gcacggagca caatagcacc tt

#cctggagt   2640

gcctgcccaa gtctccccag gctgctgtgc gctggctctt gcagaggcca gg

#ggatgagg   2700

ggcctgacca ggtgaagacg gacgagcgag tcttgcacac ggagcggggg ct

#gctgttcc   2760

gcaggcttag ccgtttcgat gcgggcacct acacctgcac cactctggag ca

#tggcttct   2820

cccagactgt ggtccgcctg gctctggtgg tgattgtggc ctcacagctg ga

#caacctgt   2880

tccctccgga gccaaagcca gaggagcccc cagcccgggg aggcctggct tc

#caccccac   2940

ccaaggcctg gtacaaggac atcctgcagc tcattggctt cgccaacctg cc

#ccgggtgg   3000

atgagtactg tgagcgcgtg tggtgcaggg gcaccacgga atgctcaggc tg

#cttccgga   3060

gccggagccg gggcaagcag gccaggggca agagctgggc agggctggag ct

#aggcaaga   3120

agatgaagag ccgggtgcat gccgagcaca atcggacgcc ccgggaggtg ga

#ggccacgt   3180

agaagggggc agaggagggg tggtcaggat gggctggggg gcccactagc ag

#cccccagc   3240

atctcccacc cacccagcta gggcagaggg gtcaggatgt ctgtttgcct ct

#tagagaca   3300

ggtgtctctg cccccacacc gctactgggg tctaatggag gggctgggtt ct

#tgaagcct   3360

gttccctgcc cttctctgtg ctcttagacc cagctggagc cagcaccctc tg

#gctgctgg   3420

cagccccaag ggatctgcca tttgttctca gagatggcct ggcttccgca ac

#acatttcc   3480

gggtgtgccc agaggcaaga gggttgggtg gttctttccc agcctacaga ac

#aatggcca   3540

ttctgagtga ccctcaaagt gggtgtgt

#

#           3568

<210> SEQ ID NO 6

<211> LENGTH: 276

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 6

atgacagact tgtccgagct accatcgaag tcttgggtct gcacgcaaag ga

#tggaatcc     60

cccatctcca ttcccaaaag tttccctacg ggagcctggt gttgtctcct cc

#ggaactgt    120

cctmgcggct gcctgttttt ccctagccat ggttactgcc tgcgggggat tc

#agcctgtg    180

aaggcagtca aggcagttca ccactgtcat caaacctaca cccctgtgtg ca

#ygcgcaca    240

cacacttgta acccagtggc acaatgcagg aattag

#

#      276

<210> SEQ ID NO 7

<211> LENGTH: 91

<212> TYPE: PRT

<213> ORGANISM: homo sapiens

<220> FEATURE:

<221> NAME/KEY: VARIANT

<222> LOCATION: (1)...(91)

<223> OTHER INFORMATION: Xaa = Any Amino Aci

#d

<400> SEQUENCE: 7

Met Thr Asp Leu Ser Glu Leu Pro Ser Lys Se

#r Trp Val Cys Thr Gln

1               5

#                10

#                15

Arg Met Glu Ser Pro Ile Ser Ile Pro Lys Se

#r Phe Pro Thr Gly Ala

20

#            25

#            30

Trp Cys Cys Leu Leu Arg Asn Cys Pro Xaa Gl

#y Cys Leu Phe Phe Pro

35

#        40

#        45

Ser His Gly Tyr Cys Leu Arg Gly Ile Gln Pr

#o Val Lys Ala Val Lys

50

#    55

#    60

Ala Val His His Cys His Gln Thr Tyr Thr Pr

#o Val Cys Xaa Arg Thr

65

#70

#75

#80

His Thr Cys Asn Pro Val Ala Gln Cys Arg As

#n

85

#                90

<210> SEQ ID NO 8

<211> LENGTH: 270

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 8

atgactgaat tgaatgattc taagtgttac gcaattagca aaagatgtct aa

#caatcact     60

ttggggatcc ggaacaagtg tggtcccagt tcaactgtgt tcctgtcaga at

#acctctgt    120

ggtgactctc tcctactacg tcagttccag aagcggggga tggaagaccc ct

#gttgtggc    180

cagcagtgct gttccatgtc ctttccagtg cactgtctcc tctgctgctc ag

#ggtcagga    240

tgcccacaca ctcctgcgcc cagcttctga

#

#          270

<210> SEQ ID NO 9

<211> LENGTH: 89

<212> TYPE: PRT

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 9

Met Thr Glu Leu Asn Asp Ser Lys Cys Tyr Al

#a Ile Ser Lys Arg Cys

1               5

#                10

#                15

Leu Thr Ile Thr Leu Gly Ile Arg Asn Lys Cy

#s Gly Pro Ser Ser Thr

20

#            25

#            30

Val Phe Leu Ser Glu Tyr Leu Cys Gly Asp Se

#r Leu Leu Leu Arg Gln

35

#        40

#        45

Phe Gln Lys Arg Gly Met Glu Asp Pro Cys Cy

#s Gly Gln Gln Cys Cys

50

#    55

#    60

Ser Met Ser Phe Pro Val His Cys Leu Leu Cy

#s Cys Ser Gly Ser Gly

65

#70

#75

#80

Cys Pro His Thr Pro Ala Pro Ser Phe

85

<210> SEQ ID NO 10

<211> LENGTH: 2024

<212> TYPE: DNA

<213> ORGANISM: homo sapiens

<400> SEQUENCE: 10

agggttagct catttttcat cagggagata catttctttc ccaaagctgt ga

#tctaggag     60

agttgccaag cagctagagt taaaaaaaat acacaaaaac cgcaaacaac at

#aattcttt    120

catgtggcat tctctccttt gtgctcatca tgcttgatga tcgctgacca gt

#tctaaaat    180

agagtccatg ggttcaagcc tttggctgtt tctgggctct tagacactta gt

#ctcacagc    240

ttgatcccaa ataattgtcc actgacagta ttcaaagggc ggaggtgcaa ga

#ctctcttt    300

ttgtaaggtg ggactaaatt ggaaaactat tgaaattcat gaaagatttc tc

#aggtttac    360

ttttgtgagc ttagcacatg tagaacattt acaaagcttt aatgtccata tc

#tgaacatg    420

tgtgctcttt taatcgaaag tcctcatttt tttttttttt tagatccctg cc

#tatctctt    480

tgacaggatc tatagtggtg gcttaaaacc taaatgtggt ctttcttttt tg

#ctttccag    540

atctttggca gggctagtat gaaacaatcc aattaacaca acttgatttc at

#ctgcttta    600

ttttgtgatt atctcttggt ggccagagcc agccctctgg accagaggaa ac

#aatgatgc    660

ccacctggtc aatggaggtt attttagttg tgagtactcg aatttgtctt gt

#gtgtaaga    720

ttccttaaag aagctgttgt ttttctgtga cctaaataag atactgttcc ca

#ggtaactt    780

tgggtctaaa aaatgacctc tttcttgggg cctttcagat gactgaattg aa

#tgattcta    840

agtgttacgc aattagcaaa agatgtctaa caatcacttt ggggatccgg aa

#caagtgtg    900

gtcccagttc aactgtgttc ctgtcagaat acctctgtgg tgactctctc ct

#actacgtc    960

agttccagaa gcgggggatg gaagacccct gttgtggcca gcagtgctgt tc

#catgtcct   1020

ttccagtgca ctgtctcctc tgctgctcag ggtcaggatg cccacacact cc

#tgcgccca   1080

gcttctgagt ctcagtctcc ccttctaggt cgcctttgca gcttcactct tt

#gtttgctc   1140

tgtggaagtt tctcgtttaa gctctgttga gtgaaaagag tgatcacaac cc

#cattggca   1200

ttttgttttc tgtttctgcg ttaattcacc taggacaatg gcctccagct gc

#atccatac   1260

tgctgcaaat gacatgattt cactcttttt tatggctgtg tagttccatg gt

#atatacat   1320

atatcacatt ttctttaccc agttcaccat tgatgggcac ctgggtttat cc

#catgtcct   1380

tgctattgtg aatagtgctg tgatgaacat gtacatgcat atgtcttttt gg

#taaaatga   1440

tttattttcc ttcgggggta tatgcagtaa tgggattgct gggtcaagtg gt

#agttttat   1500

ttttagttct ttagaaattt ccaaatgctt tccataggga ctgagctaat tt

#acttttcc   1560

accaacagtg tataagtgtt ccctttgtat gcattctcac caacatctat tt

#tttgactt   1620

tttagtaata gccattctga ctggtgtgag atgatatctc atttggtttt gg

#tttacatt   1680

ttcctgacaa ttagtgatac taagcatttt tcatgtttgt tggctgcttg ta

#tgtcttct   1740

ttttaagaag tgactgttca tgtcatttgc ccacttttta atttggttgt tt

#tttgcttg   1800

ttgaattatt taagttactt atagattctg agtgtttgcc ctttgtagga cg

#tatagttt   1860

gcaaatattt tctcccattc tgcaggttgt ctgtttagtt taatagtttc tt

#tttttgct   1920

gtgcagaaag tctttagttt aattaggtcc catttatcaa tttttgtttt tg

#ttgcaatt   1980

gcttttgagg gttcagtttt attattctgt atatggatgg tcag

#                 202

#4